Scott Stromatt

1.5k total citations
33 papers, 1.0k citations indexed

About

Scott Stromatt is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Scott Stromatt has authored 33 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Genetics, 15 papers in Pathology and Forensic Medicine and 10 papers in Immunology. Recurrent topics in Scott Stromatt's work include Chronic Lymphocytic Leukemia Research (18 papers), Lymphoma Diagnosis and Treatment (15 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Scott Stromatt is often cited by papers focused on Chronic Lymphocytic Leukemia Research (18 papers), Lymphoma Diagnosis and Treatment (15 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Scott Stromatt collaborates with scholars based in United States, Poland and Germany. Scott Stromatt's co-authors include Gareth Parry, Mark A. Ross, Carmel Armon, Jack H. Petajan, Jessie C. Goodpasture, Richard J. Barohn, Wilson W. Bryan, Rebecca Hoagland, Robert G. Miller and Sanford H. Roth and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Internal Medicine.

In The Last Decade

Scott Stromatt

32 papers receiving 974 citations

Peers

Scott Stromatt
Mauro Pluderi Italy
Mario Löhr Germany
Zhenshu Xu China
Novella Calvaresi Italy
Sara Morando Italy
W. Shawn Carbonell United States
Weiping Su China
Maria Maddalena Lino Switzerland
Tomokazu Aoki Japan
Raelene Endersby Australia
Mauro Pluderi Italy
Scott Stromatt
Citations per year, relative to Scott Stromatt Scott Stromatt (= 1×) peers Mauro Pluderi

Countries citing papers authored by Scott Stromatt

Since Specialization
Citations

This map shows the geographic impact of Scott Stromatt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Stromatt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Stromatt more than expected).

Fields of papers citing papers by Scott Stromatt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Stromatt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Stromatt. The network helps show where Scott Stromatt may publish in the future.

Co-authorship network of co-authors of Scott Stromatt

This figure shows the co-authorship network connecting the top 25 collaborators of Scott Stromatt. A scholar is included among the top collaborators of Scott Stromatt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott Stromatt. Scott Stromatt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Robak, Tadeusz, Andrzej Hellmann, Janusz Kłoczko, et al.. (2016). Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia. British Journal of Haematology. 176(4). 618–628. 30 indexed citations
2.
Gopal, Ajay K., Stefano Tarantolo, Naresh Bellam, et al.. (2014). Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. Investigational New Drugs. 32(6). 1213–1225. 19 indexed citations
3.
Smolewski, Piotr, Paweł Robak, Barbara Cebula‐Obrzut, et al.. (2014). Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies. European Journal of Cancer. 50(15). 2677–2684. 9 indexed citations
4.
Pagel, John M., Stephen E. Spurgeon, John C. Byrd, et al.. (2014). Otlertuzumab (TRU‐016), an anti‐CD37 monospecific ADAPTIR™ therapeutic protein, for relapsed or refractory NHL patients. British Journal of Haematology. 168(1). 38–45. 34 indexed citations
5.
Byrd, John C., John M. Pagel, Farrukh T. Awan, et al.. (2014). A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood. 123(9). 1302–1308. 56 indexed citations
6.
Maddocks, Kami J., John M. Pagel, Susan O’Brien, et al.. (2013). Phase 1b Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIR™ Protein, In Combination With Rituximab In Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL). Blood. 122(21). 4165–4165. 2 indexed citations
7.
Awan, Farrukh T., Ulrich Jaeger, Robert M. Rifkin, et al.. (2012). Phase 1b Study of TRU-016, an Anti-CD37 SMIP™ Protein, in Combination with Bendamustine Vs Bendamustine Alone in Relapsed Chronic Lymphocytic Leukemia. Blood. 120(21). 1795–1795. 4 indexed citations
8.
Awan, Farrukh T., John M. Pagel, André Goy, et al.. (2011). A phase Ib/II open-label study to evaluate the safety and efficacy of TRU-016 in combination with bendamustine versus bendamustine alone in patients with relapsed chronic lymphocytic leukemia.. Journal of Clinical Oncology. 29(15_suppl). e13053–e13053. 1 indexed citations
9.
Lapalombella, Rosa, Asha Ramanunni, Yuh-Ying Yeh, et al.. (2011). Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals. Blood. 118(21). 622–622. 4 indexed citations
10.
Pagel, John M., Stephen E. Spurgeon, Farrukh T. Awan, et al.. (2011). Phase 1 Study of TRU-016, An Anti-CD37 SMIP™ Protein in Relapsed and/or Refractory NHL Patients. Blood. 118(21). 1636–1636. 1 indexed citations
11.
Awan, Farrukh T., John M. Pagel, Leslie A. Andritsos, et al.. (2011). Phase 1 Study of Tru-016, An Anti-CD37 SMIP™ Protein in Naive and Relapsed and/or Refractory CLL Patients. Blood. 118(21). 1792–1792. 4 indexed citations
12.
Furman, Richard R., Leslie A. Andritsos, Ian W. Flinn, et al.. (2010). Phase 1 Dose Escalation Study of TRU-016, An Anti-CD37 SMIP™ Protein In Relapsed and Refractory CLL. Blood. 116(21). 56–56. 8 indexed citations
13.
Borchmann, Peter, Raoul Herbrecht, Martin Wilhelm, et al.. (2006). Results of a Phase II Study of Pixantrone in Combination with Cyclophosphamide, Vincristine, and Prednisone in Patients with Relapsed Aggressive Non-Hodgkin’s Lymphoma.. Blood. 108(11). 529–529. 6 indexed citations
14.
15.
Singer, Jack W., et al.. (2005). Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane. Anti-Cancer Drugs. 16(3). 243–254. 100 indexed citations
16.
Bryan, Wilson W., Rebecca Hoagland, James R. Murphy, et al.. (2003). Can we eliminate placebo in ALS clinical trials?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. 4(1). 11–15. 16 indexed citations
17.
Miller, Robert G., Jack H. Petajan, Wilson W. Bryan, et al.. (1996). A placebo‐controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. Annals of Neurology. 39(2). 256–260. 278 indexed citations
18.
Stromatt, Scott. (1993). Secretory Leukocyte Protease Inhibitor in Cystic Fibrosis. Birkhäuser Basel eBooks. 42. 103–110. 9 indexed citations
19.
Jaszewski, Richard, David Y. Graham, & Scott Stromatt. (1992). Treatment of nonsteroidal antiinflammatory drug-induced gastric ulcers with misoprostol. Digestive Diseases and Sciences. 37(12). 1820–1824. 13 indexed citations
20.
Weir, Matthew R., et al.. (1991). Minimization of Indomethacin‐Induced Reduction in Renal Function by Misoprostol. The Journal of Clinical Pharmacology. 31(8). 729–735. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mauro Pluderi Breakdown of academic impact, for papers by Mario Löhr Breakdown of academic impact, for papers by Zhenshu Xu Breakdown of academic impact, for papers by Novella Calvaresi Breakdown of academic impact, for papers by Sara Morando Breakdown of academic impact, for papers by W. Shawn Carbonell Breakdown of academic impact, for papers by Weiping Su Breakdown of academic impact, for papers by Maria Maddalena Lino Breakdown of academic impact, for papers by Tomokazu Aoki Breakdown of academic impact, for papers by Raelene Endersby
Rankless by CCL
2026